EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS (EGFR-TFI): THE NURSE'S ROLE IN MANAGEMENT OF PATIENTS RECEIVING MOLECULAR TARGETED THERAPIES.

2.50
Hdl Handle:
http://hdl.handle.net/10755/165006
Category:
Abstract
Type:
Presentation
Title:
EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS (EGFR-TFI): THE NURSE'S ROLE IN MANAGEMENT OF PATIENTS RECEIVING MOLECULAR TARGETED THERAPIES.
Author(s):
Guerrero, Maria
Author Details:
Maria Guerrero, RN MSN ANP-C OCN, APN-Post Graduate Oncology nurse fellow, MD Anderson Cancer Center, Houston, Texas, USA, email: mguerrero18@houston.rr.com
Abstract:
Molecular targeted therapy is the new and innovative method being used to treat cancer patients with solid tumors. In this particular treatment modality target molecules are focused more on its essential effects to the growth and progression of tumors, and not to its effects on normal healthy tissue. This is significantly distinguished from cytotoxic chemotherapy in which these agents do not distinguish between killing only tumors cells from normal cells; they annihilate everything leading to devastating drug related toxicities. The goal for targeted therapies is to provide antitumor benefits with better tolerability. Epidermal Growth Factor Receptor Kinase is one of many target molecules on tumor cells that is responsible for activating multiple down signaling pathways governing tumor growth. Several approaches have been created to inhibit the EGFR pathway in this particular paper we will discuss EGFR ûTKI which have been described to provide benefits in patients with solid tumors and have been associated with specific clinical features and safety profiles as compared to conventional chemotherapy toxic therapies. Molecular targeted therapies are opening many doors of opportunity for patients with advanced solid tumors while receiving chemotherapy or for the patient who may be unable to tolerate the toxicities associated with chemotherapy. Research is currently ongoing for effective plans in order to incorporate molecular therapies for patients with solid malignancies. The goal for this paper is to educate the nurse on the role of new treatment modality EGFRK and its role in the development of solid tumors. (1) identification of EGFR-TKI (2) the potential efficacy and side effects associated with molecular targeted therapies (3) Information that the nurse needs to be able identify and obtain in order to manage the potential side effects associated with this particular type of therapy, and signs and symptoms that need to reported promptly to the physician or nurse practitioner. Evaluation would be nurseÆs ability to recognize type of therapy, side effects, and need for management of potential side effects associated with this therapy. The methodology to disseminate this information will be a poster presentation depicting all three categories mentioned This presentation will be of benefit to oncology nurses who provide care to patients experiencing craniotomies and to nurses in any setting that are looking for a process to improve patient education. The Journal Club is still in its infancy stages, as we have only had two meetings. However, progress has been made, as the staff is now beginning to be more prepared in their discussion of the articles. Continued education is planned for the coming year with the goal of a totally certified oncology program. Staff has been encouraged to attend and report about various educational programs both within and outside the facility including Fall Institute and Congress. We will continue to develop programs to encourage autonomous practice through the expansion of staff skills and knowledge.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleEPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS (EGFR-TFI): THE NURSE'S ROLE IN MANAGEMENT OF PATIENTS RECEIVING MOLECULAR TARGETED THERAPIES.en_GB
dc.contributor.authorGuerrero, Mariaen_US
dc.author.detailsMaria Guerrero, RN MSN ANP-C OCN, APN-Post Graduate Oncology nurse fellow, MD Anderson Cancer Center, Houston, Texas, USA, email: mguerrero18@houston.rr.comen_US
dc.identifier.urihttp://hdl.handle.net/10755/165006-
dc.description.abstractMolecular targeted therapy is the new and innovative method being used to treat cancer patients with solid tumors. In this particular treatment modality target molecules are focused more on its essential effects to the growth and progression of tumors, and not to its effects on normal healthy tissue. This is significantly distinguished from cytotoxic chemotherapy in which these agents do not distinguish between killing only tumors cells from normal cells; they annihilate everything leading to devastating drug related toxicities. The goal for targeted therapies is to provide antitumor benefits with better tolerability. Epidermal Growth Factor Receptor Kinase is one of many target molecules on tumor cells that is responsible for activating multiple down signaling pathways governing tumor growth. Several approaches have been created to inhibit the EGFR pathway in this particular paper we will discuss EGFR ûTKI which have been described to provide benefits in patients with solid tumors and have been associated with specific clinical features and safety profiles as compared to conventional chemotherapy toxic therapies. Molecular targeted therapies are opening many doors of opportunity for patients with advanced solid tumors while receiving chemotherapy or for the patient who may be unable to tolerate the toxicities associated with chemotherapy. Research is currently ongoing for effective plans in order to incorporate molecular therapies for patients with solid malignancies. The goal for this paper is to educate the nurse on the role of new treatment modality EGFRK and its role in the development of solid tumors. (1) identification of EGFR-TKI (2) the potential efficacy and side effects associated with molecular targeted therapies (3) Information that the nurse needs to be able identify and obtain in order to manage the potential side effects associated with this particular type of therapy, and signs and symptoms that need to reported promptly to the physician or nurse practitioner. Evaluation would be nurseÆs ability to recognize type of therapy, side effects, and need for management of potential side effects associated with this therapy. The methodology to disseminate this information will be a poster presentation depicting all three categories mentioned This presentation will be of benefit to oncology nurses who provide care to patients experiencing craniotomies and to nurses in any setting that are looking for a process to improve patient education. The Journal Club is still in its infancy stages, as we have only had two meetings. However, progress has been made, as the staff is now beginning to be more prepared in their discussion of the articles. Continued education is planned for the coming year with the goal of a totally certified oncology program. Staff has been encouraged to attend and report about various educational programs both within and outside the facility including Fall Institute and Congress. We will continue to develop programs to encourage autonomous practice through the expansion of staff skills and knowledge.en_GB
dc.date.available2011-10-27T12:10:52Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:10:52Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.